Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Spectranetics Gets Canadian OK for Study of Higher Laser Parameters
Jan 2001
COLORADO SPRINGS, Colo., Jan. 15 -- The Spectranetics Corp. has received approval from the Therapeutic Products Programme (TPP) of Health Canada to expand its study of the use of higher laser energy delivered through Spectranetics' Point 9 mm catheters on difficult-to-treat coronary lesions to 100 patients. In the expanded study, coronary arteries with 80 percent or greater blockages and evidence of calcification, lesions that had previously failed balloon angioplasty, or chronic total occlusions traversable by a guidewire will be treated by Luc Bilodeau., of the Montreal Heart Institute, Montreal, Quebec, and David Hilton of the Royal Jubilee Hospital in Victoria, British Columbia.
Bilodeau and Hilton recently completed a successful pilot evaluation involving 36 patients that demonstrated increased efficacy of higher excimer parameters -- blockages were crossed 94 percent of the time using higher laser parameters, compared with 72 percent using normal laser parameters. The expanded study will provide additional data to support the successful pilot study results.FIBER

News & Featureslasers

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.